Last reviewed · How we verify
Semaglutide Pen
At a glance
| Generic name | Semaglutide Pen |
|---|---|
| Also known as | Semaglutide Pen without ADA |
| Sponsor | Unity Health Toronto |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- AMAZE 8: A Research Study Investigating How Well the Medicine NNC0487-0111 Compared to Semaglutide Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight (PHASE3)
- A Research Study to Look at How Semaglutide Compared to Placebo Affects Diabetic Eye Disease in People With Type 2 Diabetes (PHASE3)
- Glucagon-Like Peptide-1 Receptor Agonist in the Treatment of Adult, Obesity-related, Symptomatic Asthma (GATA-3) (PHASE2)
- Type 1 Diabetes Impacts of Semaglutide on Cardiovascular Outcomes (PHASE3)
- Investigating the Impact of GLP-1 RA Therapy on Osteosarcopenia in Older Female Adults With Diabetes (PHASE3)
- A Study of the Effect of (S)-Pindolol Benzoate (ACM-001.1) on Lean Body Mass (LBM) in Obese Patents During (PROACT 1), and Post-semaglutide Therapy (PROACT 2) (PHASE2)
- GLP-1 Analogue Effects on Food Cues, Stress, Motivation for Highly Palatable Foods, and Weight (PHASE1)
- A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in Children and Adolescents With Type 2 Diabetes (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Semaglutide Pen CI brief — competitive landscape report
- Semaglutide Pen updates RSS · CI watch RSS
- Unity Health Toronto portfolio CI